<DOC>
	<DOCNO>NCT02068963</DOCNO>
	<brief_summary>This non-interventional clinical study conduct prospectively collect serial plasma serum sample treatment na誰ve subject chronic HCV infection initiate sofosbuvir-based therapy . These sample use estimate clinical utility endpoint Aptima HCV Quant Dx assay use aid management HCV-infected patient undergo HCV antiviral therapy .</brief_summary>
	<brief_title>Collection Plasma Serum Samples From Individuals Initiating Sofosbuvir Chronic Hepatitis C Testing</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>The subject chronically infected HCV genotypes 1 , 2 , 3 , 4 , 5 , and/or 6 document subject 's medical record na誰ve HCV treatment ( treatment na誰ve ) . Chronic HCV ( without HIV [ human immunodeficiency virus ] coinfection ) document historical record : A positive HCV RNA test result ( result generate least 6 month baseline visit ) A HCV genotype test result ( result generate least 6 month baseline visit ) A liver biopsy report demonstrate chronic HCV The subject initiate antiviral therapy sofosbuvir regimen indicate : Sofosbuvir plus peginterferon ribavirin 12 week ( peginterferon eligible genotype 1 , 4 , 5 , 6 ) Sofosbuvir plus ribavirin 12 week ( genotype 2 ) Sofosbuvir plus ribavirin 24 week ( peginterferon ineligible unwilling genotype 1 genotype 3 ) The subject least 18 year age time enrollment Adequate medical record available collection protocoldefined demographic , baseline patient characteristic , medical history , virology specific laboratory result , information verify enrollment criterion The subject and/or legally authorize representative willing able provide consent prior provide specimen ( ) Subjects history evidence decompensated liver disease Subjects severe renal impairment end stage renal disease Subjects na誰ve HCV therapy prior exposure approve experimental HCV antiviral therapy Subject characteristic contraindicate FDA approve label sofosbuvir ( eg , subject contraindication applicable peginterferon and/or ribavirin , pregnant woman men whose female partner pregnant ; Sovaldi Package Insert 2013 ) Subject receive treatment pre posttransplant Subject unsuitable study participation base Investigator 's decision ( eg , unlikely comply study visit schedule , significant medical complication ) Participating another investigational study Investigator believe might interfere subject 's participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>